| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447454 | European Journal of Cancer | 2011 | 7 Pages |
Abstract
Interim PET/CT scanning had a significant predictive value for disease progression and survival of DLBCL in post-rituximab treatment; it might be the single most important determinant of clinical outcome in patients with the same IPI risk.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Deok-Hwan Yang, Jung-Joon Min, Ho-Chun Song, Yong Yeon Jeong, Woong-Ki Chung, Soo-Young Bae, Jae-Sook Ahn, Yeo-Kyeoung Kim, Hee-Seung Bom, Ik-Joo Chung, Hyeoung-Joon Kim, Je-Jung Lee,